F.D.A. Delays Action on Closely Watched Alzheimer’s Drug

Health Consultant March 08, 2024 0

Eli Lilly’s donanemab was expected to be approved this month, but the agency has decided to convene a panel of independent experts to evaluate the drug’s safety and efficacy.

from NYT > Health https://ift.tt/uerDs2S
via IFTTT

No comments

Subscribe to: Post Comments ( Atom )